



PTO/SB/08A/B (09-06)
Approved for use through 03/31/2007. OMB 0691-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Application Number	10/595,934-Conf. #9188
		Filing Date	May 19, 2006
		First Named Inventor	Mladen Mercep
		Art Unit	N/A
		Examiner Name	Not Yet Assigned
Sheet	1	of	2
		Attorney Docket Number	03818/0204417-USO

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No.†	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-6,511,976	01-28-2003	Andres-Gil et al.	
	AB*	US-4,145,434	03-20-1979	VAN DER Burg et al.	
	AC*	US-3,711,489	01-16-1973	Lombardino	
	AD*	US-4,198,421	04-15-1980	Cherkofsky et al.	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No.†	Foreign Patent Document Country Code ² -Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	BA	WO-99/19317	04-22-1999	Janssen Pharmaceutica N.V.	
	BB	WO-97/38991	10-23-1997	Janssen Pharmaceutica N.V.	
	BC	WO-96/14320	05-17-1996	Janssen Pharmaceutica N.V.	
	BD	WO-96/14321	05-17-1996	Janssen Pharmaceutica N.V.	
	BE	CA-967,573	05-13-1975	Pfizer Inc.	
	BF	FR-2,504,140	10-22-1982	Centre Nat Rech Scient	
	BG	EP-0063525	10-27-1982	Centre National de la Recherche Scientifique	
	BH	WO-03/099822	12-04-2003	Pliva D D et al.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. †Applicant's unique citation designation number (optional). ‡See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. §Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ¶For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. **Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ***Applicant is to place a check mark here if English language translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.†	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
	CA	Gansser C. et al., "Determination of the radioprotective activity of certain analogs of imipramine" Ann. Pharmaceutiques Francaises, 1983, vol. 41: pages 465-471			
	CB	Olivera R. et al., "Dibenzoxepino [4,5-d]pyrazoles: a facile approach via the Ullmann-ether reaction" Tetrahedron Letters, 2000, vol. 41: 4353-4356, 4357-4360			
	CC	Kawashima K. et al., "Synthesis of Dibenzo [b,f] azepine Derivatives. III. Introduction of a Cyclopropane Ring by Therman Decomposition of a Pyrazoline" Takeda Kenkyusho Ho., 1978, vol. 37, pages 6-11.			
	CD	Fichou D. et al., "Regioselective De La Cycloaddition Dipolaire—1,3" Tetrahedron, 1984, vol. 40, No. 24, pp. 5121-5133			
	CE	Saucier, C. et al. "Identification of an Endogenous 5-Hydroxytryptamine 2A Receptor in NIH-3T3 Cells: Agonist-Induced Down-Regulation Involves Decreases in Receptor RNA and Number" Journal of Neurochemistry, 1997, vol. 68, No. 1, pages 1998 - 2011			
	CF	Wolf, W.A. et al. "The Serotonin 5-HT 2C Receptor is a Prominent Serotonin Receptor in Basal Ganglia: Evidence from Functional Studies on Serotonin-Mediated Phosphoinositide Hydrolysis" Journal of Neurochemistry, 1997, vol. 69, pgs. 1449			

Examiner Signature	/Amy Lewis/	Date Considered	11/08/2009
--------------------	-------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.L./

Substitute for form 1449/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)			Application Number	10/595,934-Conf. #9188	
			Filing Date	May 19, 2006	
			First Named Inventor	Mladen Mercep	
			Art Unit	N/A	
			Examiner Name	Not Yet Assigned	
Sheet	2	of	2	Attorney Docket Number	03818/0204417-USO

CG	Thomson W. et al. "Juvenile Idiopathic Arthritis Genetics - What's new? What's next? Arthritis Research, 2002, vol. 4 and 5: pgs 302-306
CH	Millan, M.J. et al. "S18126 ((2-4-2,3-dihydrobenzo[1,4] dioxin-6-yl)piperazin-1-ylmethyl)), A Potent, Selective and Competitive Antagonist at Dopamine D4 Receptors: An In vitro and In Vitro and In Vivo Comparison with L 745,870 (3-(4-[4-chlorophenyl]piperazin-1-yl)methyl-1H-pyrrolo[2,3b]pyridine) and Raclopride, 1998, Journal of Pharmacology and Experimental Therapeutics, vol. 287: No. 1 pages 167-186.
CI	T.F. Meert, et al. " Psychopharmacology of Ritanerlin: Comparison with Chlordiazepoxide", Drug Development Research, 1989, vol. 18, pgs. 119-144
CJ	F.Bymaster, et al., " New Approaches to developing antidepressants by enhancing monoaminergic neurotransmission" Expert Opinion Investig. Drugs 2003, 12, 531-543
CK	U. Spampinato, et al. " Role of Striatal Serotonin 2A and Serotonin 2C Receptor Subtypes in the Control of In Vivo Dopamine Outflow in the Rat Striatum" J. Neurochemistry 2000, vol. 74, pgs. 693-701
CL	F.P. Monnet, et al. "N-Methyl-D-aspartate-induced neuronal activation is selectively modulated by σ receptors", European Journal of Pharmacology, 1990, vol. 179, pgs. 441-445.
CM	Claghorn, J. et al, "Recent developments in antidepressant agents" Progress in Drug Research Clin Inc. 1996, vol.46, pgs.243-262;
CN	Sperling, W. et al " New Tetracyclic Antidepressants" Drugs Today, 1997, vol. 33, No. 2, pgs. 95-102.
CO	J. Ignacio Andres et al. " R107500.A new 5-HT 2A/2C Antagonist with Potential Anxiolytic Profile" Drugs Fut. 2002, vol. 27, Suppl. A: C41
CP	Jose M. Cid, et al., " Synthesis of 2-aminomethyl-3, 3a, 8, 12, "Drugs Fut. 2002, vol 27, Suppl. A: P182
CQ	Niemegeers, C.J.E., et al, "Interaction of Drugs with Apomorphine, Tryptamine and Norepinephrine. A New "in vivo" Approach: the ATN-Test in Rats", Arch. Int. Pharmacodyn. Vol. 227, pages 238-253 (1977).
CR	Berge S. M. et al. "Pharmaceutical Salts," Journal of Pharmaceutical Sciences., 1977; Vol. 66: pages 1-20
CS	Bonhaus D.W., et al, " The pharmacology and distribution of human 5-hydroxytryptamine2B (5HT2B) receptor gene products: comparison with 5-HT2A and 5HT2C receptors" British Journal of Pharmacology. (1995), Vol. 115: pages 622-628
CT	Porsolt R.D. et al. " Behavioural Despair in Mice: A Primary Screening Test for Antidepressants" Arch. Int. Pharmacodyn. Vol. 229, pages 327-336 (1977)
CU	PCT International Search Report for International Application No. PCT/HR2004/000053, Dated April 18, 2005.
CV	Olivera, Roberto, et al., "Revisiting the Ullmann-Ether Reaction: A Concise and Amenable Synthesis of Novel Dibenzoxepino[4,5-d]pyrazoles by Intramolecular Etheration of 4,5-(α,α' -Halohydroxy) arylpyrazoles" Journal of Organic Chemistry, 2002, Vol 67, pages 7215-7225.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	/Amy Lewis/	Date Considered	11/08/2009
--------------------	-------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /A.L./



Application No. (if known): 10/595,934

Attorney Docket No.: 03818/0204417-US0

Certificate of Express Mailing Under 37 CFR 1.10

I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail, Airbill No. in an envelope addressed to:

6834731540W

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on October 20, 2006
Date

J. Stantini

Signature

J. Stantini

Typed or printed name of person signing Certificate

Registration Number, if applicable

Telephone Number

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

IDS (Citation) by Applicant (2pages) (30 References)
Information Disclosure Statement (5 pages)
Return Receipt Postcard